• Jecko Thachil.
• Department of Haematology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. jecko.thachil@cmft.nhs.uk.
• Clin Med (Lond). 2016 Apr 1; 16 (2): 152160152-60.

AbstractPlatelets play a very important role in physiological haemostasis and thrombus formation. Platelet aggregation is the key pathophysiological factor in the development of arterial ischaemic events, including coronary artery disease, cerebrovascular accidents and peripheral arterial disease. As such, antiplatelet therapy plays a very important role in preventing recurrent events in the individuals who are affected by one of these conditions. Until recently, the repertoire of antiplatelet therapy was limited to aspirin and clopidogrel. However, this landscape has changed dramatically with the advent of newer and more potent agents, prasugrel and ticagrelor and also the glycoprotein IIb/IIIa antagonists. This armamentarium is likely to expand further with the advent of protease-activated receptor-1 antagonists and the intravenous cangrelor. This review summarises the different agents available and some practical considerations for their use from a general physician's perspective.© 2016 Royal College of Physicians.

18 keywords...

hide…